RSLV-132 is an Fc fusion protein comprised of catalytically active human RNase fused to human IgG1. The drug is designed to digest the RNA colecules associated with the autoantibodies that are present in the circulation of patients with autioimmune diseases such as Sjogren’s syndrome and lupus. A positive phase 2 study has been completed in Sjogren’ syndrome and the program is being advanced in 2024 into a large phase 2b study. A phase 2a study was completed in lupus with promising results that warrant further study in a larger cohort of lupus patients.
